TP53 and Barrett esophagus: Furthermore, a separate study demonstrated that 46% of BE lesions that progress to high grade dysplasia or esophageal adenocarcinoma harbor TP53 mutations, whereas BE lesions that did not progress, only had TP53 mutations 5% of the time [21].